Kenneth Kolinsky

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

Christian Tovar, James Rosinski, Zoran Filipovic et al. · Proceedings of the National Academy of Sciences · 2006 · 699 citations · Full text

Chemoprevention Strategy, Apoptosis, Cell Death +17

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Hong Yang, Brian Higgins, Kenneth Kolinsky et al. · Cancer Research · 2010 · 400 citations

Melanoma Cell Lines, Phase Ii, Medicine +15

Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.

Kim W. McIntyre, George Stepan, Kenneth Kolinsky et al. · The Journal of Experimental Medicine · 1991 · 289 citations · Full text

Immunology, Immune Regulation, Immunologic Mechanism +20

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Christian Tovar, Bradford Graves, Kathryn Packman et al. · Cancer Research · 2013 · 280 citations

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Hong Yang, Brian Higgins, Kenneth Kolinsky et al. · Cancer Research · 2011 · 214 citations · Full text

Antitumor Activity, Cancer Biology, Tumor Biology +17